National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Bronchitol® – Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF)

Rapid Review

Commenced Completed Outcome
11/09/2012 21/09/2012 Full HTA recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
14/03/2014  29/08/2014 Reimbursement not recommended

Summary

NCPE Assessment Process Complete
Rapid Review Commissioned 02/04/2019
Rapid Review Completed 29/04/2019
Rapid Review Outcome A full HTA is not recommended. The NCPE recommends that Mannitol Dry Powder (Bronchitol®) not be considered for reimbursement, having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.